Author Correction: Gemcitabine and cisplatin plus nivolumab as organ-sparing treatment for muscle-invasive bladder cancer: a phase 2 trial

Matthew D Galsky^{1

2}, Siamak Daneshmand³, Sudeh Izadmehr⁴, Edgar Gonzalez-Kozlova⁵, Kevin G Chan⁶, Sara Lewis⁷, Bassam El Achkar⁷, Tanya B Dorff⁸, Jeremy Paul Cetnar⁹, Brock O Neil¹⁰, Anishka D'Souza¹¹, Ronac Mamtani¹², Christos Kyriakopoulos¹³, Tomi Jun^{14

15}, Mahalya Gogerly-Moragoda⁴, Rachel Brody^{16

17}, Hui Xie¹⁸, Kai Nie¹⁸, Geoffrey Kelly¹⁸, Amir Horowitz^{16

19}, Yayoi Kinoshita¹⁷, Ethan Ellis^{20

21}, Yohei Nose¹⁹, Giorgio Ioannou¹⁹, Rafael Cabal¹⁹, Diane M Del Valle¹⁹, G Kenneth Haines²², Li Wang^{4

23}, Kent W Mouw²⁴, Robert M Samstein²⁵, Reza Mehrazin²⁶, Nina Bhardwaj^{16

18

19}, Menggang Yu²⁷, Qianqian Zhao²⁷, Seunghee Kim-Schulze^{16

18

19}, Robert Sebra^{16

20

21}, Jun Zhu^{4

23}, Sacha Gnjatic^#^{16

18

19}, John Sfakianos^#²⁶, Sumanta K Pal^#⁸

Affiliations

¹ Division of Hematology and Medical Oncology, Icahn School of Medicine at Mount Sinai, New York, NY, USA. matthew.galsky@mssm.edu.
² Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA. matthew.galsky@mssm.edu.
³ Department of Urology, Keck School of Medicine of USC, Norris Comprehensive Cancer Center, Los Angeles, CA, USA.
⁴ Division of Hematology and Medical Oncology, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
⁵ Department of Oncological Sciences, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
⁶ Department of Urology, City of Hope Comprehensive Cancer Center, Duarte, CA, USA.
⁷ Department of Radiology, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
⁸ Department of Medical Oncology & Therapeutics, City of Hope Comprehensive Cancer Center, Duarte, CA, USA.
⁹ Division of Hematology and Medical Oncology, Oregon Health and Science University, Portland, OR, USA.
¹⁰ Department of Urology, University of Utah, Salt Lake City, UT, USA.
¹¹ Division of Hematology and Medical Oncology, Keck School of Medicine of USC, Norris Comprehensive Cancer Center, Los Angeles, CA, USA.
¹² Division of Hematology and Medical Oncology, University of Pennsylvania Abramson Cancer Center, Philadelphia, PA, USA.
¹³ Division of Hematology and Medical Oncology, University of Wisconsin Carbone Cancer Center, Madison, WI, USA.
¹⁴ Genentech, South San Francisco, CA, USA.
¹⁵ Formerly with the Icahn School of Medicine at Mount Sinai, New York, NY, USA.
¹⁶ Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
¹⁷ Department of Pathology, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
¹⁸ Human Immune Monitoring Center, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
¹⁹ Precision Immunology Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
²⁰ Department of Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
²¹ Icahn Institute for Data Science and Genomic Technology, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
²² Department of Pathology, Molecular and Cell-based Medicine, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
²³ Gene Dx, Stamford, CT, USA.
²⁴ Department of Radiation Oncology, Dana-Farber Cancer Institute/Brigham & Women's Hospital, Harvard Medical School, Boston, MA, USA.
²⁵ Department of Radiation Oncology, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
²⁶ Department of Urology, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
²⁷ Department of Biostatistics and Medical Informatics, University of Wisconsin Carbone Cancer Center, Madison, WI, USA.

^# Contributed equally.

PMID: 38242983
PMCID: PMC11031387
DOI: 10.1038/s41591-024-02814-0

Published Erratum

Author Correction: Gemcitabine and cisplatin plus nivolumab as organ-sparing treatment for muscle-invasive bladder cancer: a phase 2 trial

Matthew D Galsky et al. Nat Med. 2024 Apr.

. 2024 Apr;30(4):1211.

doi: 10.1038/s41591-024-02814-0.

Authors

Affiliations

¹ Division of Hematology and Medical Oncology, Icahn School of Medicine at Mount Sinai, New York, NY, USA. matthew.galsky@mssm.edu.
² Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA. matthew.galsky@mssm.edu.
³ Department of Urology, Keck School of Medicine of USC, Norris Comprehensive Cancer Center, Los Angeles, CA, USA.
⁴ Division of Hematology and Medical Oncology, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
⁵ Department of Oncological Sciences, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
⁶ Department of Urology, City of Hope Comprehensive Cancer Center, Duarte, CA, USA.
⁷ Department of Radiology, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
⁸ Department of Medical Oncology & Therapeutics, City of Hope Comprehensive Cancer Center, Duarte, CA, USA.
⁹ Division of Hematology and Medical Oncology, Oregon Health and Science University, Portland, OR, USA.
¹⁰ Department of Urology, University of Utah, Salt Lake City, UT, USA.
¹¹ Division of Hematology and Medical Oncology, Keck School of Medicine of USC, Norris Comprehensive Cancer Center, Los Angeles, CA, USA.
¹² Division of Hematology and Medical Oncology, University of Pennsylvania Abramson Cancer Center, Philadelphia, PA, USA.
¹³ Division of Hematology and Medical Oncology, University of Wisconsin Carbone Cancer Center, Madison, WI, USA.
¹⁴ Genentech, South San Francisco, CA, USA.
¹⁵ Formerly with the Icahn School of Medicine at Mount Sinai, New York, NY, USA.
¹⁶ Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
¹⁷ Department of Pathology, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
¹⁸ Human Immune Monitoring Center, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
¹⁹ Precision Immunology Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
²⁰ Department of Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
²¹ Icahn Institute for Data Science and Genomic Technology, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
²² Department of Pathology, Molecular and Cell-based Medicine, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
²³ Gene Dx, Stamford, CT, USA.
²⁴ Department of Radiation Oncology, Dana-Farber Cancer Institute/Brigham & Women's Hospital, Harvard Medical School, Boston, MA, USA.
²⁵ Department of Radiation Oncology, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
²⁶ Department of Urology, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
²⁷ Department of Biostatistics and Medical Informatics, University of Wisconsin Carbone Cancer Center, Madison, WI, USA.

^# Contributed equally.

PMID: 38242983
PMCID: PMC11031387
DOI: 10.1038/s41591-024-02814-0

No abstract available

PubMed Disclaimer

Erratum for

Gemcitabine and cisplatin plus nivolumab as organ-sparing treatment for muscle-invasive bladder cancer: a phase 2 trial.
Galsky MD, Daneshmand S, Izadmehr S, Gonzalez-Kozlova E, Chan KG, Lewis S, Achkar BE, Dorff TB, Cetnar JP, Neil BO, D'Souza A, Mamtani R, Kyriakopoulos C, Jun T, Gogerly-Moragoda M, Brody R, Xie H, Nie K, Kelly G, Horowitz A, Kinoshita Y, Ellis E, Nose Y, Ioannou G, Cabal R, Del Valle DM, Haines GK, Wang L, Mouw KW, Samstein RM, Mehrazin R, Bhardwaj N, Yu M, Zhao Q, Kim-Schulze S, Sebra R, Zhu J, Gnjatic S, Sfakianos J, Pal SK. Galsky MD, et al. Nat Med. 2023 Nov;29(11):2825-2834. doi: 10.1038/s41591-023-02568-1. Epub 2023 Oct 2. Nat Med. 2023. PMID: 37783966 Free PMC article. Clinical Trial.

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Author Correction: Gemcitabine and cisplatin plus nivolumab as organ-sparing treatment for muscle-invasive bladder cancer: a phase 2 trial

Affiliations

Author Correction: Gemcitabine and cisplatin plus nivolumab as organ-sparing treatment for muscle-invasive bladder cancer: a phase 2 trial

Authors

Affiliations

Erratum for

Publication types

Grants and funding

LinkOut - more resources

Full Text Sources